Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.45 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.45 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.45 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.44 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.44 |
| ▸ | SELP | P16109 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1900343 | 1.00 | PRKCA (0.45) | PRKCAPRKCEPRKCQPRKCDS1PR1 | |
| SCHEMBL1556453 | 1.00 | PRKCA (0.45) | PRKCAPRKCEPRKCQPRKCDS1PR1 | |
| SCHEMBL2126025 | 0.86 | PRKCE (0.61) | PRKCAPRKCEPRKCQPRKCDENPP2 | |
| SCHEMBL1867684 | 0.81 | P2RY10 (0.42) | P2RY10GPR34 | |
| SCHEMBL1864332 | 0.81 | P2RY10 (0.42) | P2RY10GPR34 | |
| SCHEMBL2329616 | 0.81 | P2RY10 (0.42) | P2RY10GPR34 | |
| SCHEMBL190727 | 0.81 | ENPP2 (0.64) | ENPP2P2RY10GPR34 | |
| SCHEMBL16714278 | 0.81 | ENPP2 (0.64) | ENPP2P2RY10GPR34 | |
| SCHEMBL3645476 | 0.80 | ENPP2 (0.57) | ENPP2P2RY10GPR34 | |
| SCHEMBL14659956 | 0.80 | PRKCA (0.56) | PRKCAPRKCEPRKCQPRKCDENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110305769-A1 | BRANCHED CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM | ENZON PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110305770-A1 | RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM | ENZON PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110229581-A1 | RELEASABLE CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | ENZON PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110223257-A1 | RELEASABLE FUSOGENIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | ENZON PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| EP-2362728-A1 | RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM | Enzon Pharmaceuticals, Inc. (US) | 2011-09-07 | — | — | EP | disclosed |
| EP-2355799-A1 | RELEASABLE FUSOGENIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | Enzon Pharmaceuticals, Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20110111044-A1 | NANOPARTICLE COMPOSITIONS FOR NUCLEIC ACIDS DELIVERY SYSTEM | ENZON PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2010057150-A1 | RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | ENZON PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010057160-A1 | RELEASABLE FUSOGENIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | ENZON PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110305769-A1 | BRANCHED CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM | NPC1L1, CETP, SREBF2 | PRKCA 4035/4885PRKCE 4281/4885PRKCQ 3750/4885 |
| US-20110229581-A1 | RELEASABLE CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | APLNR, LPAR6, ABHD16A | PRKCA 2896/4885PRKCE 3833/4885PRKCQ 2620/4885 |
| US-20110305770-A1 | RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM | KPNA6, LPAR6, KAT6B | PRKCA 3223/4885PRKCE 4158/4885PRKCQ 3663/4885 |
| US-20110223257-A1 | RELEASABLE FUSOGENIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | FUS, HNRNPUL2, HNRNPDL | PRKCA 4357/4885PRKCE 4490/4885PRKCQ 3899/4885 |
| US-20110111044-A1 | NANOPARTICLE COMPOSITIONS FOR NUCLEIC ACIDS DELIVERY SYSTEM | FUS, NUP205, SNX9 | PRKCA 3729/4885PRKCE 4412/4885PRKCQ 3681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.